Phase II Randomized Study of Abiraterone Acetate Plus ADT Versus APALUTAMIDE Versus Abiraterone and APALUTAMIDE in Patients With Advanced Prostate Cancer With Non-castrate Testosterone Levels

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 21 Feb 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Abiraterone acetate (Primary) ; Apalutamide (Primary) ; Goserelin; Prednisone
Indications Adenocarcinoma; Prostate cancer
Focus Proof of concept; Therapeutic Use

13 Oct 2023 According to Janssen Pharmaceuticals media release, Janssen Pharmaceuticals has changed its name to Johnson & Johnson Innovative Medicine.
07 Jun 2022 Results assessing the outcomes of 2 year-overall survival (2y-OS) and time-to-treatment failure (TTF) presented at the 58th Annual Meeting of the American Society of Clinical Oncology
13 Oct 2021 Results published in the European Journal of Cancer

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com